{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:15:27Z","timestamp":1791918927602,"version":"4.3.4"},"reference-count":70,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.drudis.2025.104367","type":"journal-article","created":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T19:16:54Z","timestamp":1745608614000},"page":"104367","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Targeting FLT3 for treating diseases: FLT3 inhibitors"],"prefix":"10.1016","volume":"30","author":[{"given":"Qing-Yun","family":"Rong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo-Wu","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quan","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2025.104367_b0005","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s40164-021-00207-4","article-title":"Profiling of somatic mutations and fusion genes in acute myeloid leukemia patients with FLT3-ITD or FLT3-TKD mutation at diagnosis reveals distinct evolutionary patterns","volume":"10","author":"Guan","year":"2021","journal-title":"Exp Hematol Oncol"},{"key":"10.1016\/j.drudis.2025.104367_b0010","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1182\/blood-2002-02-0492","article-title":"The roles of FLT3 in hematopoiesis and leukemia","volume":"100","author":"Gilliland","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2025.104367_b0015","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1002\/cncr.30140","article-title":"Does FLT3 mutation impact survival after hematopoietic stem cell transplantation for acute myeloid leukemia? A center for international blood and marrow transplant research (CIBMTR) analysis","volume":"122","author":"Deol","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.drudis.2025.104367_b0020","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.ejmech.2019.06.002","article-title":"Dual FLT3 inhibitors: against the drug resistance of acute myeloid leukemia in recent decade","volume":"178","author":"Yuan","year":"2019","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.drudis.2025.104367_b0025","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/cas.14274","article-title":"FLT3 mutations in acute myeloid leukemia: therapeutic paradigm beyond inhibitor development","volume":"111","author":"Kiyoi","year":"2020","journal-title":"Cancer Sci"},{"key":"10.1016\/j.drudis.2025.104367_b0030","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/bjh.18877","article-title":"Mutation spectrum of FLT3 and significance of non-canonical FLT3 mutations in haematological malignancy","volume":"202","author":"Ge","year":"2023","journal-title":"Br J Haematol"},{"key":"10.1016\/j.drudis.2025.104367_b0035","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1021\/acs.jmedchem.8b01714","article-title":"Virtual screening identifies irreversible FMS-like tyrosine kinase 3 inhibitors with activity toward resistance-conferring mutations","volume":"62","author":"Bensinger","year":"2019","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2025.104367_b0040","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1152\/physrev.00029.2018","article-title":"FMS-like tyrosine kinase 3\/FLT3: from basic science to clinical implications","volume":"99","author":"Kazi","year":"2019","journal-title":"Physiol Rev"},{"key":"10.1016\/j.drudis.2025.104367_b0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2023.104139","article-title":"FLT3 inhibitors and novel therapeutic strategies to reverse AML resistance: an updated comprehensive review","volume":"191","author":"Abdel-Aziz","year":"2023","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.drudis.2025.104367_b0050","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2025.104367_b0055","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1158\/1535-7163.MCT-16-0876","article-title":"FLT3 inhibitors in acute myeloid leukemia: current status and future directions","volume":"16","author":"Larrosa-Garcia","year":"2017","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.drudis.2025.104367_b0060","doi-asserted-by":"crossref","DOI":"10.1177\/2040620719827310","article-title":"Emerging treatment paradigms with FLT3 inhibitors in acute myeloid leukemia","volume":"10","author":"Short","year":"2019","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.drudis.2025.104367_b0065","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/s12967-017-1281-x","article-title":"Molecular targeting in acute myeloid leukemia","volume":"15","author":"Lim","year":"2017","journal-title":"J Transl Med"},{"key":"10.1016\/j.drudis.2025.104367_b0070","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation","volume":"377","author":"Stone","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2025.104367_b0075","doi-asserted-by":"crossref","first-page":"3146","DOI":"10.1080\/10428194.2020.1805109","article-title":"Updated safety of midostaurin plus chemotherapy in newly diagnosed FLT3 mutation-positive acute myeloid leukemia: the RADIUS-X expanded access program","volume":"61","author":"Roboz","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.drudis.2025.104367_b0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.106037","article-title":"Properties of FDA-approved small molecule protein kinase inhibitors: a 2022 update","volume":"175","author":"Roskoski","year":"2022","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.drudis.2025.104367_b0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2021.116596","article-title":"Discovery of a benzimidazole-based dual FLT3\/TrKA inhibitor targeting acute myeloid leukemia","volume":"56","author":"Dokla","year":"2022","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.drudis.2025.104367_b0090","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1182\/blood-2020-137334","article-title":"Results of a Phase 2, randomized, double-blind study of sorafenib versus placebo in combination with intensive chemotherapy in previously untreated patients with FLT3-ITD acute myeloid leukemia (ALLG AMLM16)","volume":"136","author":"Wei","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2025.104367_b0095","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.ejca.2017.09.016","article-title":"Long-term survival of sorafenib-treated FLT3-ITD-positive acute myeloid leukaemia patients relapsingafter allogeneic stem cell transplantation","volume":"86","author":"Metzelder","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.drudis.2025.104367_b0100","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/nm.4484","article-title":"Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells","volume":"24","author":"Mathew","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.drudis.2025.104367_b0105","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s13065-023-00981-8","article-title":"Indole-based FLT3 inhibitors and related scaffolds as potential therapeutic agents for acute myeloid leukemia","volume":"17","author":"Ezelarab","year":"2023","journal-title":"BMC Chem"},{"key":"10.1016\/j.drudis.2025.104367_b0110","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1038\/s41375-021-01177-6","article-title":"FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearranged infant acute lymphoblastic leukemia: Children\u2019s Oncology Group trial AALL0631","volume":"35","author":"Brown","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.drudis.2025.104367_b0115","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s40265-019-1062-3","article-title":"Gilteritinib: first global approval","volume":"79","author":"Dhillon","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.drudis.2025.104367_b0120","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1007\/s10637-017-0470-z","article-title":"Gilteritinib, a FLT3\/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia","volume":"35","author":"Mori","year":"2017","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.drudis.2025.104367_b0125","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.beha.2018.09.008","article-title":"What FLT3 inhibitor holds the greatest promise?","volume":"31","author":"Stone","year":"2018","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.drudis.2025.104367_b0130","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1007\/s40262-020-00888-w","article-title":"Pharmacokinetic profile of gilteritinib: a novel FLT-3 tyrosine kinase inhibitor","volume":"59","author":"James","year":"2020","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.drudis.2025.104367_b0135","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.ccell.2021.06.003","article-title":"The AML microenvironment catalyzes a stepwise evolution to gilteritinib resistance","volume":"39","author":"Joshi","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.drudis.2025.104367_b0140","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.3324\/haematol.2019.244020","article-title":"Venetoclax combines synergistically with FLT3 inhibition to effectively target leukemic cells in FLT3-ITD+ acute myeloid leukemia models","volume":"106","author":"Singh Mali","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.drudis.2025.104367_b0145","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1182\/blood-2022-157210","article-title":"Updated results from a phase I\/II study of the triplet combination of azacitidine, venetoclax and gilteritinib for patients with FLT3-mutated acute myeloid leukemia","volume":"140","author":"Short","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2025.104367_b0150","doi-asserted-by":"crossref","first-page":"3647","DOI":"10.3390\/jcm12113647","article-title":"Gilteritinib: the story of a proceeding success into hard-to-treat FLT3-mutated AML patients","volume":"12","author":"Molica","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.drudis.2025.104367_b0155","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s40364-022-00447-4","article-title":"Sitravatinib as a potent FLT3 inhibitor can overcome gilteritinib resistance in acute myeloid leukemia","volume":"11","author":"Zhang","year":"2023","journal-title":"Biomark Res"},{"key":"10.1016\/j.drudis.2025.104367_b0160","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s12185-024-03730-2","article-title":"JSH practical guidelines for hematological malignancies, 2023: I. Leukemia-1. Acute myeloid leukemia (AML)","volume":"119","author":"Maeda","year":"2024","journal-title":"Int J Hematol"},{"key":"10.1016\/j.drudis.2025.104367_b0165","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2025.104367_b0170","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.2147\/DDDT.S198950","article-title":"Quizartinib (AC220): a promising option for acute myeloid leukemia","volume":"13","author":"Zhou","year":"2019","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.drudis.2025.104367_b0175","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1080\/14656566.2020.1801637","article-title":"Quizartinib for the treatment of acute myeloid leukemia","volume":"21","author":"Garcia-Horton","year":"2020","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.drudis.2025.104367_b0180","doi-asserted-by":"crossref","first-page":"3885","DOI":"10.2217\/fon-2019-0353","article-title":"Quizartinib in the treatment of FLT3-internal-tandem duplication-positive acute myeloid leukemia","volume":"15","author":"Paul","year":"2019","journal-title":"Future Oncol"},{"key":"10.1016\/j.drudis.2025.104367_b0185","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/S0140-6736(23)00464-6","article-title":"Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-first): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Erba","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.drudis.2025.104367_b0190","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1200\/JCO.23.01061","article-title":"Crenolanib and intensive chemotherapy in adults with newly diagnosed FLT3-mutated AML","volume":"42","author":"Wang","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.drudis.2025.104367_b0195","doi-asserted-by":"crossref","first-page":"12708","DOI":"10.3390\/ijms232012708","article-title":"Clinical efficacies of FLT3 inhibitors in patients with acute myeloid leukemia","volume":"23","author":"Song","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.drudis.2025.104367_b0200","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s00280-022-04412-8","article-title":"Population pharmacokinetics of crenolanib in children and young adults with brain tumors","volume":"89","author":"Bisbee","year":"2022","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.drudis.2025.104367_b0205","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1158\/1541-7786.MCR-20-0600","article-title":"Crenolanib regulates ERK and AKT\/mTOR signaling pathways in RAS\/BRAF-mutated colorectal cancer cells and organoids","volume":"19","author":"Fujino","year":"2021","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.drudis.2025.104367_b0210","doi-asserted-by":"crossref","first-page":"7007","DOI":"10.1200\/JCO.2022.40.16_suppl.7007","article-title":"Long-term results of a phase 2 trial of crenolanib combined with 7+3 chemotherapy in adults with newly diagnosed FLT3 mutant AML","volume":"40","author":"Wang","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.drudis.2025.104367_b0215","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.1158\/1078-0432.CCR-21-4450","article-title":"Preclinical and pilot study of type I FLT3 tyrosine kinase inhibitor, crenolanib, with sorafenib in acute myeloid leukemia and FLT3-internal tandem duplication","volume":"28","author":"Inaba","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.drudis.2025.104367_b0220","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, adaptive, and acquired resistance to cancer immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.drudis.2025.104367_b0225","doi-asserted-by":"crossref","first-page":"245","DOI":"10.3390\/biomedicines8080245","article-title":"Mechanisms underlying resistance to FLT3 inhibitors in acute myeloid leukemia","volume":"8","author":"Eguchi","year":"2020","journal-title":"Biomedicines"},{"key":"10.1016\/j.drudis.2025.104367_b0230","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/bjh.12599","article-title":"Bone marrow stroma-mediated resistance to FLT3 inhibitors in FLT3-ITD AML is mediated by persistent activation of extracellular regulated kinase","volume":"164","author":"Yang","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.drudis.2025.104367_b0235","doi-asserted-by":"crossref","first-page":"4817","DOI":"10.3390\/cancers14194817","article-title":"Nerve density and neuronal biomarkers in cancer","volume":"14","author":"Ali","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.drudis.2025.104367_b0240","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1182\/bloodadvances.2018022921","article-title":"Role of CYP3A4 in bone marrow microenvironment-mediated protection of FLT3\/ITD AML from tyrosine kinase inhibitors","volume":"3","author":"Chang","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.drudis.2025.104367_b0245","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/nature11016","article-title":"Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia","volume":"485","author":"Smith","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2025.104367_b0250","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1158\/2159-8290.CD-18-1453","article-title":"Clonal selection with RAS pathway activation mediates secondary clinical resistance to selective FLT3 inhibition in acute myeloid leukemia","volume":"9","author":"McMahon","year":"2019","journal-title":"Cancer Discov"},{"key":"10.1016\/j.drudis.2025.104367_b0255","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.588876","article-title":"Emergence of BCR- ABL1 fusion in AML post-FLT3 inhibitor-based therapy: a potentially targetable mechanism of resistance \u2013 a case series","volume":"10","author":"Alotaibi","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.drudis.2025.104367_b0260","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1182\/blood.2020007626","article-title":"Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin","volume":"137","author":"Schmalbrock","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2025.104367_b0265","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.3324\/haematol.2018.205385","article-title":"Hematopoietic niche drives FLT3-ITD acute myeloid leukemia resistance to quizartinib via STAT5-and hypoxia-dependent upregulation of AXL","volume":"104","author":"Dumas","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.drudis.2025.104367_b0270","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/s41467-018-08263-x","article-title":"Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms","volume":"10","author":"Zhang","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.drudis.2025.104367_b0275","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.1500221","article-title":"Pim kinases modulate resistance to FLT3 tyrosine kinase inhibitors in FLT3-ITD acute myeloid leukemia","volume":"1","author":"Green","year":"2015","journal-title":"Sci Adv"},{"key":"10.1016\/j.drudis.2025.104367_b0280","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1182\/blood-2017-05-786657","article-title":"A novel irreversible FLT3 inhibitor, FF-10101, shows excellent efficacy against AML cells with FLT3 mutations","volume":"131","author":"Yamaura","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2025.104367_b0285","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1007\/s13402-022-00703-7","article-title":"Combination of RSK inhibitor LJH-685 and FLT3 inhibitor FF-10101 promoted apoptosis and proliferation inhibition of AML cell lines","volume":"45","author":"Zhang","year":"2022","journal-title":"Cell Oncol"},{"key":"10.1016\/j.drudis.2025.104367_b0290","doi-asserted-by":"crossref","first-page":"7041","DOI":"10.2147\/OTT.S171640","article-title":"Clinical use of FLT3 inhibitors in acute myeloid leukemia","volume":"11","author":"Sutamtewagul","year":"2018","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.drudis.2025.104367_b0295","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.3324\/haematol.2022.280884","article-title":"Concomitant targeting of FLT3 and BTK overcomes FLT3 inhibitor resistance in acute myeloid leukemia through the inhibition of autophagy","volume":"108","author":"Zhang","year":"2023","journal-title":"Haematologica"},{"key":"10.1016\/j.drudis.2025.104367_b0300","doi-asserted-by":"crossref","first-page":"5953","DOI":"10.1182\/blood-2023-181151","article-title":"A phase 1a\/b trial of luxeptinib (CG-806) in patients with relapsed\/refractory B-cell malignancies or acute myeloid leukemia and evaluation of new G3 formulation","volume":"142","author":"Goldberg","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2025.104367_b0305","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1158\/0008-5472.CAN-15-1580","article-title":"The dual MEK\/FLT3 inhibitor E6201 exerts cytotoxic activity against acute myeloid leukemia cells harboring resistance-conferring FLT3 mutations","volume":"76","author":"Zhang","year":"2016","journal-title":"Cancer Res"},{"key":"10.1016\/j.drudis.2025.104367_b0310","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1038\/s41416-018-0099-5","article-title":"Safety, pharmacokinetics, and preliminary efficacy of E6201 in patients with advanced solid tumours, including melanoma: results of a phase 1 study","volume":"118","author":"Tibes","year":"2018","journal-title":"Br J Cancer"},{"key":"10.1016\/j.drudis.2025.104367_b0315","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nrd.2016.211","article-title":"Induced protein degradation: an emerging drug discovery paradigm","volume":"16","author":"Lai","year":"2017","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2025.104367_b0320","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.chembiol.2017.10.005","article-title":"A chemoproteomic approach to query the degradable kinome using a multi-kinase degrader","volume":"25","author":"Huang","year":"2018","journal-title":"Cell Chem Biol"},{"key":"10.1016\/j.drudis.2025.104367_b0325","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.105508","article-title":"Degrading FLT3-ITD protein by proteolysis targeting chimera (PROTAC)","volume":"119","author":"Chen","year":"2022","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.drudis.2025.104367_b0330","doi-asserted-by":"crossref","first-page":"16428","DOI":"10.1021\/jacs.8b10320","article-title":"Enhancing antiproliferative activity and selectivity of a FLT-3 inhibitor by proteolysis targeting chimera conversion","volume":"140","author":"Burslem","year":"2018","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.drudis.2025.104367_b0335","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1021\/acsmedchemlett.2c00402","article-title":"Development of gilteritinib-based chimeric small molecules that potently induce degradation of FLT3-ITD protein","volume":"13","author":"Ohoka","year":"2022","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.drudis.2025.104367_b0340","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.canlet.2018.01.071","article-title":"Combined inhibition of PI3K\u03b4 and FLT3 signaling exerts synergistic antitumor activity and overcomes acquired drug resistance in FLT3-activated acute myeloid leukemia","volume":"420","author":"He","year":"2018","journal-title":"Cancer Lett"},{"key":"10.1016\/j.drudis.2025.104367_b0345","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1002\/ajh.25198","article-title":"Sorafenib combined with 5-azacytidine in older patients with untreated FLT3-ITD mutated acute myeloid leukemia","volume":"93","author":"Ohanian","year":"2018","journal-title":"Am J Hematol"},{"key":"10.1016\/j.drudis.2025.104367_b0350","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.3324\/haematol.2020.263392","article-title":"A phase I\/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome","volume":"106","author":"Swaminathan","year":"2021","journal-title":"Haematologica"}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644625000807?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644625000807?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T16:20:17Z","timestamp":1758126017000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644625000807"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":70,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S1359644625000807"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2025.104367","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting FLT3 for treating diseases: FLT3 inhibitors","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2025.104367","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104367"}}